Publications by authors named "Francisco Arnaiz-de Las Revillas"
Clinical Management and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients: A Multinational Case-control Study.
Transplantation
July 2024
Article Synopsis
- A study analyzed the management and mortality outcomes of nontuberculous mycobacterial (NTM) infections in solid organ transplant (SOT) recipients, focusing on data from 2008 to 2018.
- Out of 85 patients with NTM infections and 169 matched controls, one-year mortality was significantly higher in the infected group (20%) compared to controls (3%), particularly among those who had lung transplants.
- Factors like time to treatment and changes in immunosuppression levels did not show a direct correlation with mortality rates among the patients.
Isavuconazole Versus Voriconazole as the First-line Therapy for Solid Organ Transplant Recipients With Invasive Aspergillosis: Comparative Analysis of 2 Multicenter Cohort Studies.
Transplantation
November 2024
Article Synopsis
- Isavuconazole (ISA) and voriconazole (VORI) are both recommended first-line treatments for invasive aspergillosis, but there hasn't been a direct comparison in solid organ transplant recipients.
- A study analyzed data from two cohorts of patients treated with either ISA or VORI, focusing on clinical response, mortality rates, adverse events, and treatment discontinuation after 12 weeks.
- Results showed no significant difference in clinical outcomes between ISA and VORI, but ISA had fewer adverse events and lower rates of treatment discontinuation, indicating better tolerability.
Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.
Open Forum Infect Dis
March 2024
Background: Several aspects of the occurrence and management of mycotic aneurysm (MA) in patients with infective endocarditis (IE) have not been studied.
Objectives: To determine the incidence and factors associated with MA presence and rupture and to assess the evolution of those initially unruptured MA.
Methods: Prospective multicenter cohort including all patients with definite IE between January 2008 and December 2020.
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.
Lancet Infect Dis
April 2024
Background: De-escalation from broad-spectrum to narrow-spectrum antibiotics is considered an important measure to reduce the selective pressure of antibiotics, but a scarcity of adequate evidence is a barrier to its implementation. We aimed to determine whether de-escalation from an antipseudomonal β-lactam to a narrower-spectrum drug was non-inferior to continuing the antipseudomonal drug in patients with Enterobacterales bacteraemia.
Methods: An open-label, pragmatic, randomised trial was performed in 21 Spanish hospitals.
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.
Int J Antimicrob Agents
September 2023
Objectives: Infective endocarditis (IE) has high mortality and morbidity and requires long hospital stays to deliver the antibiotic treatment recommended in clinical practice guidelines. We aimed to analyse the health outcomes of the use of dalbavancin (DBV) in the consolidation treatment of IEs caused by Gram-positive cocci and to perform a pharmacoeconomic study.
Materials And Methods: This observational, retrospective, Spanish multicentre study in patients with IE who received DBV as part of antibiotic treatment in consolidation phase were followed for at least 12 months.
Background. Infective endocarditis (IE) is a severe condition. Our aim was to describe the profile and prognosis of patients with multivalvular infective endocarditis (MIE) and compare them to single-valve IE (SIE).
View Article and Find Full Text PDFArticle Synopsis
- Infective Endocarditis (IE) is a serious illness, and diabetes mellitus (DM) has been linked to worse outcomes for patients with IE.
- A study analyzing data from the Spanish IE Registry (2008−2020) found that almost 30% of IE patients had DM, with higher in-hospital and one-year mortality rates for those with DM compared to those without.
- The presence of organ damage in DM patients further increases the risks of mortality, indicating that diabetes management is crucial for improving prognosis in these patients.
Article Synopsis
- During the COVID-19 pandemic, researchers studied various immune system components to identify biomarkers that could predict disease severity in patients infected with SARS-CoV-2.
- The study involved 155 patients who were classified into mild or severe cases based on their need for oxygen therapy, revealing that severe cases were associated with older age and higher levels of several inflammatory markers.
- A predictive model created from factors like age, ferritin, and lymphocyte counts demonstrated an ability to predict severe disease with an accuracy of 78%, suggesting that certain immune parameters may serve as potential prognostic indicators for COVID-19.
Article Synopsis
- The study aimed to evaluate the effectiveness of the COVID-GRAM and CURB-65 scores in predicting the severity of COVID-19 in Caucasian patients.
- A total of 523 patients were analyzed, revealing that a higher COVID-GRAM score significantly correlated with increased rates of critical illness and mortality compared to CURB-65 scores.
- The findings suggest that the COVID-GRAM score is a reliable tool for assessing the risk of severe illness in these patients, with the CURB-65 score serving as a useful alternative.
Objectives: Coronavirus disease 2019 (COVID-19) survivors are reporting residual abnormalities after discharge from hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. This study aimed to describe lung function in patients recovering from COVID-19 hospitalization and to identify biomarkers in serum and induced sputum samples from these patients.
View Article and Find Full Text PDFBackground: Daptomycin is a bactericidal antibiotic approved for the treatment of skin and soft tissue infections and right-side endocarditis. However, there is a lack of published data outlining its usefulness in vascular graft infections (VGI). The aim of this study was to describe the clinical experience of daptomycin use in the treatment of VGI caused by Gram-positive bacteria.
View Article and Find Full Text PDF